DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/qq4w5q/zebinix) has announced the addition of GlobalData's new report "Zebinix (Epilepsy) - Forecast and Market Analysis to 2022" to their offering.
Zebinix (Epilepsy) - Forecast and Market Analysis to 2022.
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period.
Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.
Eslicarbazepine acetate (ESL) is a drug developed by Bial - Portela & CA, S.A. that has been approved for marketing in Europe, where it was launched by the company in conjuction with Eisai in 2009. The drug is still awaiting FDA approval in the US, where it is being developed and commercialized by Sunovion Pharmaceuticals under the brand name Stedesa. ESL is a third-generation, single-enantiomer member of the commonly prescribed first-line dibenzazepine family of AEDs.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Zebinix performance - Obtain sales forecast for Zebinix from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and India)
Key Topics Covered:
1 Tables & Figures
Go here to see the original:
Research and Markets: Zebinix ( Epilepsy ) - Forecast and Market Analysis to 2022 with UCB and GlaxoSmithKline Currently ...